Takeda Pharmaceutical Company Limited (TAK) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - Specialty & Generic Branche. Der Hauptsitz des Unternehmens ist in Tokyo, Japan. Der aktuelle CEO ist Christophe Weber.
TAK hat IPO-Datum 2010-01-05, 49,281 Vollzeitbeschäftigte, gelistet an der NYSE, eine Marktkapitalisierung von $56.39B.
Takeda Pharmaceutical Company Limited is a globally diversified pharmaceutical company headquartered in Tokyo, Japan, with operations across North America, Europe, Latin America, Russia, and Asia. Founded in 1781, Takeda engages in the research, development, manufacturing, and commercialization of pharmaceutical products across key therapeutic areas including gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. The company markets numerous branded products such as Entyvio, Velcade, Adcetris, and Trintellix, and maintains an extensive portfolio of strategic collaborations and licensing agreements with leading biotech firms and research institutions to support its pipeline development and innovation initiatives.
